March 10, 2025

HEIDELBERG UNIVERSITY HOSPITAL AMONG THE WORLD’S BEST HOSPITALS IN 2025

HEIDELBERG UNIVERSITY HOSPITAL AMONG THE WORLD’S BEST HOSPITALS IN 2025
Go back

The US magazine “Newsweek” has once again named Heidelberg University Hospital (UKHD) one of the best hospitals in the world. In the “World’s Best Hospitals 2025” ranking, which is compiled by “Newsweek” in collaboration with the statistics and data platform “Statista”, the UKHD ranks 14th out of 2,400 hospitals worldwide. In Germany, the UKHD is in second place, just behind the Berlin Charité.

The assessment by Newsweek is based on the opinions of healthcare experts, patient surveys and key performance indicators of the evaluated hospitals. The ranking compared hospitals from 30 countries, including Germany, the United States, Canada, England and Switzerland. In total, more than 2,400 hospitals worldwide were included in the comparison.

Worldwide comparison

Germany-wide comparison

Our latest News

discover more
New Collaborative Research Centre on Cancers of Blood-Forming Bone Marrow

New Collaborative Research Centre on Cancers of Blood-Forming Bone Marrow

DFG funds research consortium at the Medical Faculty Heidelberg with around 15.8 million euros – A new Collaborative Research Centre based at the Medical Faculty Heidelberg is going to start at Heidelberg University. In its recent approval round, the German Research Foundation (DFG) decided to support CRC 1709 “Cellular Plasticity in Malignant Myeloid Diseases – […]

read more
Strategic alliance for rare diseases: RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe

Strategic alliance for rare diseases: RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe

Heidelberg/Germany, May 27, 2025. RHEACELL announced today that it has entered into an exclusive partnership agreement with the AOP Health Group, who will commercialize RHEACELL’s two stem cell products, EBESANAR® and AMESANAR®, in Europe, Turkey, Israel and the MENA region (Middle East and Northern Africa). RHEACELL retains full commercialization rights to EBESANAR® and AMESANAR® in […]

read more
Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators. In a […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp